Drugs / MaaT033
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05889572 | Jun 2023 → Jul 2024 | amyotrophic lateral sclerosis | MaaT Pharma | Completed | No outcome recorded |
| Phase 1 | NCT04150393 | Oct 2020 → Dec 2021 | chemotherapy-induced toxicity, hematologic disorder | MaaT Pharma | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07001618 | Nov 2025 → Sep 2030 expected | non-small cell lung carcinoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT05762211 | Oct 2023 → Oct 2026 expected | disease related to hematopoietic stem cell transplant | MaaT Pharma | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05654753 | Mar 2024 → Sep 2027 expected | spondyloarthropathy | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MaaT033 | “MaaT033®, a lyophilized full-ecosystem intestinal microbiota delayed release oral capsule containing native, donor-derived (pooled from 4-6 donors) microbiome product...” NCT05654753 ↗ |
| Known as | Pooled allogeneic fecal microbiotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05762211 ↗ |
| Action | Restore | “aims to restore gut microbiota” NCT07001618 ↗ |
| Modality | Other / unclassified | “a pooled, allogeneic, lyophilized, and standardized fecal microbiotherapeutic product” PMID 40197991 ↗ Aug 2025 |
| Route | Oral | “formulated as a delayed-release capsule for oral administration” PMID 40197991 ↗ Aug 2025 |